Tarsus (NASDAQ: TARS) CMO gains 2,511 shares in RSU settlement

Rhea-AI Filing Summary

Tarsus Pharmaceuticals Chief Medical Officer Elizabeth Yeu acquired shares through the vesting and settlement of Restricted Stock Units (RSUs). On March 15, 2026, 2,511 RSUs were settled into 2,511 shares of common stock at a conversion price of $0.00 per share.

Following these transactions, she held 7,534 RSUs and 24,452 shares of common stock directly. She also had indirect ownership of 6,360 common shares through a spouse’s Roth IRA and 12,040 common shares through a 401(k) plan.

According to the RSU grant terms, awarded on March 5, 2025 under the 2020 Stock Plan, 25% of the RSUs vest on March 15 of each of 2026, 2027, 2028 and 2029, subject to her continuous service.

Insider Trade Summary

2,511 shares exercised/converted

Mixed 4 txns

Insider Lin Elizabeth Yeu

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	2,511	$0.00	--
Exercise	Common Stock	2,511	$0.00	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Units — 7,534 shares (Direct); Common Stock — 24,452 shares (Direct); Common Stock — 6,360 shares (Indirect, By Spouse's Roth IRA)

Footnotes (1)

1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Elizabeth Yeu

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

15440 LAGUNA CANYON ROAD, SUITE 160

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/15/2026		M		2,511	A	(1)	24,452	D
Common Stock								6,360	I	By Spouse's Roth IRA
Common Stock								12,040	I	By 401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	03/15/2026		M			2,511	(3)	(3)	Common Stock	2,511	$0	7,534	D

Explanation of Responses:

1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

2. Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

3. RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

Remarks:

	/s/ Jeffrey Farrow, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Tarsus (TARS) Chief Medical Officer Elizabeth Yeu report in this Form 4?

She reported an RSU vesting and share acquisition. On March 15, 2026, 2,511 Restricted Stock Units settled into 2,511 shares of Tarsus common stock at $0.00 per share, increasing her directly held common shares to 24,452.

How many Tarsus (TARS) Restricted Stock Units does Elizabeth Yeu hold after this filing?

She held 7,534 RSUs after the transaction. The Form 4 shows a derivative position of 7,534 Restricted Stock Units remaining following the March 15, 2026 settlement of 2,511 RSUs into common stock under the company’s 2020 Stock Plan.

What is the vesting schedule for Elizabeth Yeu’s Tarsus (TARS) RSU grant?

The RSUs vest in four equal annual installments. RSUs granted on March 5, 2025 vest 25% on March 15 of 2026, 2027, 2028 and 2029, provided she maintains continuous service with Tarsus Pharmaceuticals throughout the vesting period.

What are Elizabeth Yeu’s total direct and indirect Tarsus (TARS) share holdings?

She holds both direct and indirect Tarsus shares. After the transaction, she directly owned 24,452 common shares and 7,534 RSUs, plus indirect holdings of 6,360 common shares via a spouse’s Roth IRA and 12,040 common shares via a 401(k) plan.

Did this Tarsus (TARS) Form 4 show any open-market buys or sells by Elizabeth Yeu?

No open-market purchases or sales are shown. The filing records an exercise/conversion of 2,511 RSUs into common stock at $0.00 per share, along with updated direct and indirect holdings, but no transactions marked as open-market buys or sells.

How were the settled Tarsus (TARS) RSUs described in the Form 4 footnotes?

The footnotes explain the RSU settlement mechanics. They state that shares were issued pursuant to settlement of vested RSUs and that each RSU represents a contingent right to receive one share of Tarsus common stock, consistent with the 2020 Stock Plan grant terms.